A murine xenograft model for a transmissible cancer in tasmanian devils

Veterinary Pathology

Volumn 48, Issue 2, 2011, Pages 475-481

  Kreiss, A ^a   Tovar, C ^a   Obendorf, D L ^b   Dun, K ^c   Woods, G M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

Author keywords

cytogenetic; devil facial tumor disease; NOD SCID mouse; Tasmanian devil

Indexed keywords

MEMBRANE PROTEIN; PERIAXIN; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; DISEASE TRANSMISSION; ENDANGERED SPECIES; FACE TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MARSUPIAL; METABOLISM; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; ENDANGERED SPECIES; FACIAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MARSUPIALIA; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS; SARCOPHILUS HARRISII;

EID: 79953796087     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985810380398     Document Type: Article

References (22)

1. Balson GA, Croy BA, Ross TL, Yager JA: Demonstration of equine immunoglobulin in sera from severe combined immunodeficiency/beige mice inoculated with equine lymphocytes. Vet Immunol Immunopathol 39:315-325, 1993.
2. Barch MJ, Knutsen T., Spurbeck JL: The AGT Cytogenetics Laboratory Manual, 3rd ed., p. 666. Lippincott-Raven, Philadelphia, PA, 1997.
3. De Guise S., Levin MJ: Cetacean-reconstituted severe combined immunodeficient (SCID) mice respond to vaccination with canine distemper vaccine. Vet Immunol Immunopathol 97:177-186, 2004.
4. Greenwood JD: Xenogeneic PBL-scid mice: their potential and current limitations. Lab Anim Sci 43:151-155, 1993.
5. Greenwood JD, Croy BA, Trout DR, Wilcock BP: Xenogeneic (bovine) peripheral blood leukocytes engrafted into severe combined immunodeficient mice retain primary immune function. Vet Immunol Immunopathol 59:93-112, 1997.
6. Greiner DL, Shultz LD, Yates J., Appel MC, Perdrizet G., Hesselton RM, Schweitzer I., Beamer WG, Shultz KL, Pelsue SC: Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am J Pathol 146:888-902, 1995.
7. Harmelin A., Pinthus JH, Katzir N., Kapon A., Volcani Y., Amariglio EN, Rehavi G.: Use of a murine xenograft model for canine transmissible venereal tumor. Am J Vet Res 62:907-911, 2001.
8. Hawkins CE, Baars C., Hesterman H., Hocking GJ, Jones ME, Lazenby B., Mann D., Mooney N., Pemberton D., Pyecroft S., Restani M., Wiersma J.: Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol Conserv 131:307-324, 2006.
9. Holmes JM: Measurement of the rate of death of canine transmissible venereal tumour cells transplanted into dogs and nude mice. Res Vet Sci 30:248-250, 1981.
10. Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM: Interactions of host IL-6 and IFN-gamma and cancer-derived TGFbeta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 57:1091-1104, 2008.
11. Hsiao YW, Liao KW, Hung SW, Chu RM: Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGFbeta 1 and restores the lymphokine-activated killing activity. J Immunol 172:1508-1514, 2004.
12. Kreiss A., Fox N., Bergfeld J., Quinn SJ, Pyecroft S., Woods GM: Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol 32:544-553, 2008.
13. Kreiss A., Wells B., Woods GM: The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet Immunol Immunopathol 130:135-137, 2009.
14. Loh R., Bergfeld J., Hayes D., O'Hara A., Pyecroft S., Raidal S., Sharpe R.: The pathology of devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet Pathol 43: 890-895, 2006.
15. McCallum H., Tompkins DM, Jones M., Lachish S., Marvanek S., Lazenby B., Hocking G., Wiersma J., Hawkins CE: Distribution and impacts of Tasmanian devil facial tumor disease. Ecohealth 4:318-325, 2007.
16. Mosier DE, Gulizia RJ, Baird SM, Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256-259, 1988.
17. Murchison EP, Tovar C., Hsu A., Bender HS, Kheradpour P., Rebbeck CA, Obendorf D., Conlan C., Bahlo M., Blizzard CA, Pyecroft S., Kreiss A., Kellis M., Stark A., Harkins TT, Marshall Graves JA, Woods GM, Hannon GJ, Papenfuss AT: The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 327:84-87, 2010.
18. Murgia C., Pritchard JK, Kim SY, Fassati A., Weiss RA: Clonal origin and evolution of a transmissible cancer. Cell 126: 477-487, 2006.
19. Murphy WJ, Taub DD, Longo DL: The huPBL-SCID mouse as a means to examine human immune function in vivo. Semin Immunol 8:233-241, 1996.
20. Pearse AM, Swift K.: Allograft theory: transmission of devil facial-tumour disease. Nature 439:549, 2006.
21. Pyecroft SB, Pearse AM, Loh R., Swift K., Belov K., Fox N., Noonan E., Hayes D., Hyatt A., Wang L., Boyle D., Church J., Middleton D., Moore R.: Towards a case definition for devil facial tumour disease: What is it? Ecohealth 4:346-351, 2007.
22. Siddle HV, Kreiss A., Eldridge MD, Noonan E., Clarke CJ, Pyecroft S., Woods GM, Belov K.: Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci U S A 104: 16221-16226, 2007.